5% Surge Near 52-Week Low: The 'Hidden Champion' of Laboratories

Avantor Inc. (NYSE: AVTR) shares closed at $8.33, up 5.44% from the previous day, lifting its market capitalization by about $324 million to roughly $5.6 billion. Trading volume for the session reached 4.02 million shares.

In its February release of fourth-quarter 2025 results, Avantor reported revenue that slightly beat market expectations but recorded an annual net loss after a large goodwill impairment. Citing the company’s conservative 2026 guidance, Bank of America subsequently cut its price target to $11.

Meanwhile, activist investor Engine Capital has stepped up pressure for a restructuring, and Avantor’s CEO and other senior executives have been buying significant amounts of the company’s stock over recent months to support the share price and shore up investor confidence.

Headquartered in Radnor, Pennsylvania, Avantor is a life-sciences and high-value chemicals company supplying ultra-pure chemicals, laboratory consumables, and single-use bioprocessing components to the pharmaceutical, biotech, and advanced-technology industries. Because most of its revenue comes from materials and services used repeatedly in research and production, the company is viewed as having a business model that generates relatively stable cash flow even amid economic fluctuations.